SG Americas Securities LLC Sells 4,823 Shares of Guardant Health, Inc. (NASDAQ:GH)

SG Americas Securities LLC decreased its holdings in Guardant Health, Inc. (NASDAQ:GH) by 17.5% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 22,778 shares of the company’s stock after selling 4,823 shares during the quarter. SG Americas Securities LLC’s holdings in Guardant Health were worth $616,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. CWM LLC lifted its position in Guardant Health by 137.1% in the 3rd quarter. CWM LLC now owns 984 shares of the company’s stock valued at $29,000 after acquiring an additional 569 shares in the last quarter. BluePath Capital Management LLC purchased a new position in shares of Guardant Health in the 3rd quarter worth approximately $35,000. Acadian Asset Management LLC bought a new position in shares of Guardant Health in the first quarter valued at approximately $37,000. Captrust Financial Advisors increased its position in shares of Guardant Health by 33.2% during the second quarter. Captrust Financial Advisors now owns 1,087 shares of the company’s stock valued at $44,000 after acquiring an additional 271 shares during the last quarter. Finally, Belpointe Asset Management LLC lifted its holdings in Guardant Health by 33.3% during the first quarter. Belpointe Asset Management LLC now owns 3,049 shares of the company’s stock worth $71,000 after acquiring an additional 761 shares during the period. Institutional investors own 92.60% of the company’s stock.

Guardant Health Price Performance

NASDAQ GH opened at $19.70 on Thursday. The company has a market cap of $2.40 billion, a PE ratio of -4.60 and a beta of 0.87. Guardant Health, Inc. has a 52 week low of $16.92 and a 52 week high of $41.06. The company has a quick ratio of 6.24, a current ratio of 6.54 and a debt-to-equity ratio of 7.18. The firm’s 50-day simple moving average is $20.35 and its two-hundred day simple moving average is $24.07.

Guardant Health (NASDAQ:GH) last released its quarterly earnings data on Thursday, February 22nd. The company reported ($1.58) EPS for the quarter, missing the consensus estimate of ($0.93) by ($0.65). The business had revenue of $155.05 million for the quarter, compared to analysts’ expectations of $151.71 million. Guardant Health had a negative net margin of 85.02% and a negative return on equity of 301.94%. Research analysts predict that Guardant Health, Inc. will post -3.49 earnings per share for the current year.

Analyst Ratings Changes

A number of equities research analysts have recently commented on GH shares. Piper Sandler lowered their target price on Guardant Health from $40.00 to $30.00 and set an “overweight” rating on the stock in a research note on Monday, February 26th. The Goldman Sachs Group cut their price target on shares of Guardant Health from $43.00 to $37.00 and set a “buy” rating on the stock in a report on Monday, January 29th. JPMorgan Chase & Co. cut their price target on shares of Guardant Health from $60.00 to $45.00 and set an “overweight” rating on the stock in a report on Friday, February 23rd. Guggenheim began coverage on shares of Guardant Health in a report on Thursday, December 14th. They issued a “neutral” rating on the stock. Finally, Wolfe Research began coverage on shares of Guardant Health in a report on Wednesday, December 13th. They issued a “peer perform” rating on the stock. Two research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. Based on data from MarketBeat, Guardant Health has an average rating of “Moderate Buy” and a consensus price target of $41.30.

Insider Transactions at Guardant Health

In other news, insider Kumud Kalia purchased 2,187 shares of the stock in a transaction dated Monday, March 18th. The shares were purchased at an average cost of $17.82 per share, with a total value of $38,972.34. Following the completion of the acquisition, the insider now owns 12,722 shares in the company, valued at approximately $226,706.04. The transaction was disclosed in a document filed with the SEC, which is available at this link. Insiders own 6.20% of the company’s stock.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.